303
Participants
Start Date
January 31, 2017
Primary Completion Date
September 30, 2022
Study Completion Date
November 30, 2022
Cryoballoon-based PVI
Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
Anti-Arrhythmic Drug Therapy
Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Libin CV, Calgary
Royal Alexandra, Edmonton
St Paul's Hospital, Vancouver
Vancouver General, Vancouver
Royal Jubillee, Victoria
QE II, Halifax
Hamilton Health Sciences, Hamilton
St. Mary's, Kitchener
LHSC, London
Southlake, Newmarket
Ottawa Hospital, Ottawa
Rouge Valley, Scarborough Village
St. Michael's, Toronto
McGill, Montreal
Sacre-Coeur, Montreal
Laval, Québec
CHUS Le Centre hospitalier universitaire de Sherbrooke, Sherbrooke
U Saskatchewan, Saskatoon
Collaborators (1)
Ottawa Heart Institute Research Corporation
OTHER
Medtronic
INDUSTRY
University of British Columbia
OTHER